Market Overview

Bernstein: It's Time For Gilead To Pull The Trigger On This Acquisition

Share:
Bernstein: It's Time For Gilead To Pull The Trigger On This Acquisition

Bernstein analyst Geoffrey Porges said it's time for Gilead Sciences, Inc. (NASDAQ: GILD) to continue the biotech M&A with a bid for Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Porges noted that many investors "remain heavily exposed to mid and large cap biotech stocks" expecting further consolidation in the industry.

That should come from a Gilead acquisition of Vertex. Porges pegged the transaction at $45 billion, roughly a 50 percent premium to Vertex's $30.4 billion market capitalization at Monday's close ($125.55). At that price, a deal would be accretive after 2017 assuming a 27 percent cost savings. In 2015, the deal would be 7 or 8 percent dilutive to Gilead stock.

Related Link: Oppenheimer Is Excited About These 3 Biotech Stocks

The deal would also fill Gilead's need for $5 to $7 billion in "incremental revenue by 2020," according to Porges. Very few companies fit that bill, and Porges said that Vertex has "by far the best profile" and would complement Gilead's existing portfolio.

Porges estimated that a deal would move Gilead's stock to $130-140, up 30 to 40 percent from Monday's $100.65 closing price.

In pre-market activity, Vertex last traded at $128.95, up 2.7 percent. Gilead gained 0.7 percent to $101.39.

Image credit: Jeffrey Beall, Wikimedia

Latest Ratings for GILD

DateFirmActionFromTo
Nov 2019Initiates Coverage OnHold
Oct 2019MaintainsOutperform
Oct 2019DowngradesBuyHold

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Bernstein Gilead Sciences Vertex Pharmaceuticals Inc.Analyst Color Biotech Analyst Ratings General Best of Benzinga

 

Related Articles (GILD + VRTX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MJP MorganMaintains13.0
IPARDA DavidsonMaintains76.0
BSBRUBSUpgrades
TGTMorgan StanleyMaintains130.0
VCMorgan StanleyMaintains52.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Morgan Stanley Upgrades Align Technology To Overweight

Benzinga's Top Downgrades